[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]  Wall St Engine [@wallstengine](/creator/twitter/wallstengine) on x 71.9K followers Created: 2025-07-10 09:10:00 UTC Goldman Sachs Resumes Coverage on $ALT with Sell Rating, PT $X Analyst comments: "We resume coverage of Altimmune (ALT) at Sell, with a 12-month price target of $X representing XX% downside to the stock (versus XX% average upside across our coverage). ALT's lead asset, pemvidutide, is a dual GLP-1/GCGR agonist in development for the treatment of obesity and related co-morbid indications, with the company emphasizing its potential in liver-specific diseases including metabolic dysfunction-associated steatohepatitis (MASH), alcohol liver disease, and alcohol use disorder. While we view this strategy as appropriate given the role of GCGR agonism within the liver, data to date has not demonstrated a meaningfully differentiated profile for pemvidutide in either obesity or MASH. We broadly subscribe to the view that there will be room for multiple agents in these indications; however, ALT will rely on (i) a partner, or (ii) additional funding to execute against these development priorities. Given the lack of differentiation of pemvidutide against a crowded clinical landscape, we see challenges for ALT to execute the full clinical development program required to bring pemvidutide to market." Analyst: Corinne Johnson XXXXX engagements  **Related Topics** [alts](/topic/alts) [alternative investment](/topic/alternative-investment) [alt](/topic/alt) [$alt](/topic/$alt) [goldman sachs](/topic/goldman-sachs) [stocks financial services](/topic/stocks-financial-services) [alt aptoslaunch token](/topic/alt-aptoslaunch-token) [coins dao](/topic/coins-dao) [Post Link](https://x.com/wallstengine/status/1943236250405867816)
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
Wall St Engine @wallstengine on x 71.9K followers
Created: 2025-07-10 09:10:00 UTC
Goldman Sachs Resumes Coverage on $ALT with Sell Rating, PT $X
Analyst comments: "We resume coverage of Altimmune (ALT) at Sell, with a 12-month price target of $X representing XX% downside to the stock (versus XX% average upside across our coverage). ALT's lead asset, pemvidutide, is a dual GLP-1/GCGR agonist in development for the treatment of obesity and related co-morbid indications, with the company emphasizing its potential in liver-specific diseases including metabolic dysfunction-associated steatohepatitis (MASH), alcohol liver disease, and alcohol use disorder. While we view this strategy as appropriate given the role of GCGR agonism within the liver, data to date has not demonstrated a meaningfully differentiated profile for pemvidutide in either obesity or MASH. We broadly subscribe to the view that there will be room for multiple agents in these indications; however, ALT will rely on (i) a partner, or (ii) additional funding to execute against these development priorities. Given the lack of differentiation of pemvidutide against a crowded clinical landscape, we see challenges for ALT to execute the full clinical development program required to bring pemvidutide to market."
Analyst: Corinne Johnson
XXXXX engagements
Related Topics alts alternative investment alt $alt goldman sachs stocks financial services alt aptoslaunch token coins dao